NCT02091310View on ClinicalTrials.gov

Phase I Study to Evaluate the Effect of GFT505 on QT/QTc Interval in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

December 31, 2014

Study Completion Date

February 28, 2015

Conditions
Healthy Volunteers
Interventions
DRUG

Placebo

DRUG

GFT505

DRUG

Moxifloxacin 400 mg

Trial Locations (1)

38610

Eurofins Optimed, Gières

Sponsors

Lead Sponsor

Genfit
All Listed Sponsors
collaborator

Eurofins Optimed

INDUSTRY

collaborator

CardiaBase

OTHER

collaborator

PhinC Development

INDUSTRY

lead

Genfit

INDUSTRY